Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 10/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6316803 | 0.92 | ROCK2 (0.46) | HCRTR1HCRTR2MAPTALDH1A1 | |
| SCHEMBL6315541 | 0.92 | GSK3B (0.46) | HCRTR1HCRTR2KDRCDK2GSK3B | |
| SCHEMBL6324039 | 0.85 | ALDH1A1 (0.52) | CDK2GSK3BMAPTHDAC1LMNA | |
| SCHEMBL6315348 | 0.85 | ADRB2 (0.46) | CDK2GSK3BMAPTHDAC1LMNA | |
| SCHEMBL6323609 | 0.84 | ADORA2A (0.48) | CDK2GSK3BHDAC1LMNAALDH1A1 | |
| SCHEMBL6323629 | 0.84 | MET (0.44) | CDK2GSK3BMAPTHDAC1LMNA | |
| SCHEMBL6316520 | 0.84 | MAPT (0.52) | HCRTR1HCRTR2CDK2GSK3BMAPT | |
| SCHEMBL6323365 | 0.84 | CDK2 (0.47) | CDK2GSK3BMAPTHDAC1LMNA | |
| SCHEMBL6321897 | 0.83 | SMN1; SMN2 (0.47) | HCRTR1HCRTR2HDAC1LMNAALDH1A1 | |
| SCHEMBL6324450 | 0.83 | NTRK1 (0.45) | HDAC1LMNAKDM4EGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | claimed |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | MAP3K9, MAP3K19, MAP4K2 | TACR1 4879/4885HCRTR1 4375/4885HCRTR2 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.